Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial Christopher Butler , F.D. Richard Hobbs , Oghenekome Gbinigie , Najib M. Rahman , Gail Hayward , Duncan Richards , Jienchi Dorward , David Lowe , Joseph F. Standing , Judith Breuer , Saye Khoo , Stavros Petrou , Kerenza Hood , Jonathan S. Nguyen-Van-Tam , Mahendra Patel , Benjamin R. Saville , Joe Marion , Emma Ogburn , Julie Allen , Heather Rutter , Nick Francis , Nicholas Thomas , Philip Evans , Melissa Dobson , Tracie-Ann Madden , Jane Holmes , Victoria Harris , May Ee Png , Mark Lown , Oliver van Hecke , Michelle Detry , Christina Saunders , Mark Fitzgerald , Nicholas Berry , Lazaro Mwandigha , Ushma Galal , Bhautesh Jani , Nigel Hart , Daniel Butler , Jeremy Chalk , Layla Lavallee , Elizabeth Hadley , Lucy Cureton , Magdalena Benysek , Monique Andersson , Maria Coates , Sarah Barrett , Clare Bateman , Jennifer Davies , Ivy Raymundo-Wood , Andrew Ustianowski , Andrew Carson-Stevens , Ly-Mee Yu , Paul Little SSRN Electronic Journal（2022）
关键词
molnupiravir, early treatment, panoramic, open-label
AI 理解论文
溯源树
样例
